Equities

Eli Lilly and Co

0Q1G:LSE

Eli Lilly and Co

  • Price (CHF)460.00
  • Today's Change460.00 / --
  • Shares traded3.00
  • 1 Year change--
  • Beta0.4034
Data delayed at least 20 minutes, as of Sep 03 2025 15:29 BST.
More ▼

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

  • Revenue in USD (TTM)65.18bn
  • Net income in USD20.64bn
  • Incorporated1901
  • Employees47.00k
  • Location
    Eli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285United StatesUSA
  • Phone+1 (317) 276-2000Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0Q1G:LSE since
announced		Transaction
value
Ventyx Biosciences IncAnnounced07 Jan 202607 Jan 2026Announced-56.77%1.01bn
Adverum Biotechnologies IncAnnounced24 Oct 202524 Oct 2025Announced-43.97%274.32m
Verve Therapeutics IncDeal completed17 Jun 202517 Jun 2025Deal completed-43.04%1.25bn
SiteOne Therapeutics IncDeal completed27 May 202527 May 2025Deal completed-35.55%1.00bn
Data delayed at least 20 minutes, as of Sep 03 2025 15:29 BST.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.